72752-54-6

Basic information

• Product Name: 2-PIPERIDINOBENZYLAMINE
• Synonyms: ART-CHEM-BB B022095;BUTTPARK 95\50-95;AKOS B022095;2-PIPERIDINOBENZYLAMINE;RARECHEM AL BW 0505;2-Piperidin-1-ylbenzylamine;2-(1-Piperidinyl)Benzenemethanamine;BenzeneMethanaMine, 2-(1-piperidinyl)-
• CAS NO: 72752-54-6
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Mol File: 72752-54-6.mol

Chemical Properties

• Boiling Point: 329.5°C at 760 mmHg
• Flash Point: 135.8°C
• Appearance: /
• Density: 1.047g/cm³
• Vapor Pressure: 0.000177mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Store under an inert atmosphere
• CAS DataBase Reference: 2-PIPERIDINOBENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PIPERIDINOBENZYLAMINE(72752-54-6)
• EPA Substance Registry System: 2-PIPERIDINOBENZYLAMINE(72752-54-6)

Safety Data

• Hazard Codes: C
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 72752-54-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-PIPERIDINOBENZYLAMINE is used as a building block in organic synthesis for the preparation of various biologically active molecules and pharmaceuticals. Its unique structure allows it to be a versatile component in the creation of a wide range of compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-PIPERIDINOBENZYLAMINE is used as a precursor for the synthesis of various derivatives with pharmacological properties. Its potential to contribute to the development of new drugs makes it a valuable compound for research and development efforts aimed at discovering novel therapeutic agents.
Used in Drug Development:
2-PIPERIDINOBENZYLAMINE is utilized in drug development due to its structural features and potential biological activities. Its role in this process is to serve as a starting point for the design and synthesis of new pharmaceuticals, which may lead to advancements in the treatment of various diseases and conditions.

InChI:InChI=1/C12H18N2/c13-10-11-6-2-3-7-12(11)14-8-4-1-5-9-14/h2-3,6-7H,1,4-5,8-10,13H2

Upstream product

• 873-32-5 2-Chlorobenzonitrile 
• 110-89-4 piperidine 
• 394-47-8 2-fluorobenzonitrile 
• 72752-52-4 2-(piperidin-1-yl)benzonitrile 

Downstream Products

• 1258268-89-1 C₂₄H₂₄ClN₃O 
• 1028336-81-3 4-chloro-6-(2-piperidin-1-yl-benzylamino)-2H-phthalazin-1-one 
• 219922-30-2 ethyl 2-ethoxy-4-<2-<<2-cycloheptyl-1-<2-(1-piperidinyl)phenyl>ethyl>amino>-2-oxoethyl>-benzoate 
• 219922-29-9 ethyl 2-ethoxy-4-<2-<<2-cyclopentyl-1-<2-(1-piperidinyl)phenyl>ethyl>amino>-2-oxoethyl>-benzoate 
• 1026685-39-1 [2-Cycloheptyl-1-(2-piperidin-1-yl-phenyl)-ethyl]-[1-(2-piperidin-1-yl-phenyl)-meth-(E)-ylidene]-amine 
• 219922-28-8 ethyl 2-ethoxy-4-<2-<<2-cyclobutyl-1-<2-(1-piperidinyl)phenyl>ethyl>amino>-2-oxoethyl>-benzoate 
• 219922-27-7 ethyl 2-ethoxy-4-<2-<<2-cyclopropyl-1-<2-(1-piperidinyl)phenyl>ethyl>amino>-2-oxoethyl>-benzoate 
• 219922-24-4 ethyl 2-ethoxy-4-<2-<<3-methyl-1-<2-(1-piperidinyl)phenyl>3-buten-1-yl>amino>-2-oxoethyl>-benzoate 
• 219922-23-3 ethyl 2-ethoxy-4-<2-<<1-<2-(1-piperidinyl)phenyl>4-penten-1-yl>amino>-2-oxoethyl>-benzoate 

Relevant articles and documents

Aminoborohydrides. 12. Novel tandem SNAr amination-reduction reactions of 2-halobenzonitriles with lithium N,N-dialkylaminoborohydrides

A novel tandem amination-reduction reaction has been developed in which 2-(N,N-dialkylamino)benzylamines are generated from 2-halobenzonitriles and lithium N,N-dialkylaminoborohydride (LAB) reagents. These reactions are believed to occur through a tandem SNAr amination-reduction mechanism wherein the LAB reagent promotes halide displacement by the N,N-dialkylamino group, and the nitrile is subsequently reduced. This one-pot procedure is complimentary to existing synthetic methods and is an attractive synthetic tool for the nucleophilic aromatic substitution of halobenzenes with less nucleophilic amines. The (N,N-dialkylamino)benzylamine products of this reaction are easily isolated after a simple aqueous workup procedure in very good to excellent yields.

Repaglinide and related hypoglycemic benzoic acid derivatives

The structure-activity relationships in two series of hypoglycemic benzoic acid derivatives (5, 6) were investigated. Series 5 resulted from meglitinide (3) when the 2-methoxy was replaced by an alkyleneimino residue. Maximum activity was observed with the cis-3,5-dimethylpiperidino (5h) and the octamethyleneimino (5l) residues. Series 6 resulted from the meglitinide analogon 4 bearing an inversed amido function when the 2-methoxy, the 5- fluoro, and the α-methyl residue were replaced by a 2-piperidino, a 5- hydrogen, and a larger α-alkyl residue, respectively. An alkoxy residue ortho to the carboxy group further increased activity and duration of action in the rat. The most active racemic compound, 6al (R4 = isobutyl; R = ethoxy), turned out to be 12 times more active than the sulfonylurea (SU) glibenclamide (1). Activity was found to reside predominantly in the (S)- enantiomers. Compared with the SUs 1 and 2 (glimepiride), the most active enantiomer, (S)-6al (AG-EE 623 ZW; repaglinide; ED50 = 10 μg/kg po), is 25 and 18 times more active. Repaglinide turned out to be a useful therapeutic for type 2 diabetic patients; approval was granted recently by the FDA and the EMEA. From investigations on the pharmacophoric groups in compounds of type 5 and 6, it was concluded that in addition to the two already known - the acidic group (COOH; S02NH) and the amidic spacer (CONH; NHCO) - the ortho residue R1 (alkyleneimino; alkoxy; oxo) must be regarded as a third one. A general pharmacophore model suitable for hypoglycemic benzoic acid derivatives, SUs, and sulfonamides is proposed (Figure 6). Furthermore, from superpositions of low-energy conformations (LECs) of 1, 2, and (S)-6al, it was concluded that a common binding conformation (LEC II; Figure 10B) may exist and that differences in binding to the SU receptor and in the mechanism of insulin release between repaglinide and the two SUs may be due to specific hydrophobic differences.